Klaria Pharma Holding AB appointed Chief Executive Officer of Klaria Pharma (Klaria) as of November 28, 2019. He brings over 25 years of international commercial experience in the biotechnology and pharmaceutical industry to Klaria. He will succeed Scott Boyer, who will continue his full-time involvement with the company in the newly created role of Chief Scientific Officer.

The appointment comes as Klaria enters a new stage of growth with a strong commercial focus. In the coming two years the company will likely receive the approval of its first medicine, Sumatriptan Alginate Film for the treatment of acute migraine. In addition, multiple pipeline programs will likely advance into clinical development.

To ensure this growth, Klaria is now increasing the focus on out-licensing to pharmaceutical companies and also on financing. Given his 25 year track record and network in the biotech and pharmaceutical industry, the appointment of Jesper Wiklund is an important first step in this transformation of Klaria.